Physician profile
James I Meyer
NPI 1194762153
$1,345.84
in general payments reported to CMS, 2019-2025
14 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $12.53 · 2023: $50.65 · 2024: $716 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $548 · Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $547.83 |
| Food and Beverage | $386.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $886.61 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $76.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $73.86 | 2019 | |
| Glaxosmithkline, LLC. | $54.83 | 2019 | |
| Medtronic, INC. | $47.62 | 2024 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $39.21 | 2019 | |
| Mylan Specialty L.P. | $35.60 | 2019 | |
| Veran Medical Technologies, INC. | $30.58 | 2019-2020 | |
| Genzyme Corporation | $22.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.76 | 2019 | |
| Circassia INC. | $13.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.